The clinical trial study by Oki et al. showed that CUDC-907, with or without rituximab, demonstrated similar safety profiles in patients with R/R DLBCL, with a particular focus on those with MYC-altered disease. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.